111 related articles for article (PubMed ID: 10392298)
1. Urokinase-type plasminogen activator and plasminogen activator inhibitor antigen in tissue extracts of paranasal sinus mucous membranes affected by chronic sinusitis and antrochoanal polyps.
Sunagawa M; Kinjoh K; Nakamura M; Kosugi T
Eur Arch Otorhinolaryngol; 1999; 256(5):237-41. PubMed ID: 10392298
[TBL] [Abstract][Full Text] [Related]
2. Presence of urokinase-type plasminogen activator (u-PA) in tissue extracts of antrochoanal polyp.
Yamashiro Y; Nakamura M; Huang GW; Kosugi T
Laryngoscope; 1992 Sep; 102(9):1049-52. PubMed ID: 1518351
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination.
Nagayama M; Sato A; Hayakawa H; Urano T; Takada Y; Takada A
Cancer; 1994 Mar; 73(5):1398-405. PubMed ID: 8111706
[TBL] [Abstract][Full Text] [Related]
4. Expression profiles of fibrinolytic components in nasal mucosa.
Sejima T; Madoiwa S; Mimuro J; Sugo T; Ishida T; Ichimura K; Sakata Y
Histochem Cell Biol; 2004 Jul; 122(1):61-73. PubMed ID: 15197554
[TBL] [Abstract][Full Text] [Related]
5. The expression of fibrinolytic components in chronic paranasal sinus disease.
Sejima T; Holtappels G; Bachert C
Am J Rhinol Allergy; 2011; 25(1):1-6. PubMed ID: 21711960
[TBL] [Abstract][Full Text] [Related]
6. Studies on proactivator from the paranasal mucous membrane in chronic sinusitis.
Kosugi T; Takagi I; Kinjo K; Ura M; Okamoto K; Sueno K; Mihara H
Rhinology; 1983 Dec; 21(4):309-13. PubMed ID: 6686718
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators in human nasal polyps and mucosa.
Larsen K; de Maat MP; Jespersen J
Rhinology; 1997 Dec; 35(4):175-7. PubMed ID: 9532638
[TBL] [Abstract][Full Text] [Related]
8. Production of urokinase-type plasminogen activator (u-PA) and plasminogen activator inhibitor-1 (PAI-1) in human brain tumours.
Arai Y; Kubota T; Nakagawa T; Kabuto M; Sato K; Kobayashi H
Acta Neurochir (Wien); 1998; 140(4):377-85; discussion 385-6. PubMed ID: 9689330
[TBL] [Abstract][Full Text] [Related]
9. Purification and characterization of tissue-type plasminogen activator in maxillary mucosa with chronic inflammation.
Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
Thromb Haemost; 1985 Aug; 54(2):485-9. PubMed ID: 3936218
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolytic components in nasal mucosa and nasal secretion.
Yasuda T; Sakata Y; Madoiwa S; Mimuro J; Matsuda M; Kitamura K
Histochem Cell Biol; 1998 Nov; 110(5):449-55. PubMed ID: 9826124
[TBL] [Abstract][Full Text] [Related]
11. Localization of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, 2 and plasminogen in colon cancer.
Naitoh H; Eguchi Y; Ueyama H; Kodama M; Hattori T
Jpn J Cancer Res; 1995 Jan; 86(1):48-56. PubMed ID: 7737909
[TBL] [Abstract][Full Text] [Related]
12. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
13. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
Hofmann R; Lehmer A; Buresch M; Hartung R; Ulm K
Cancer; 1996 Aug; 78(3):487-92. PubMed ID: 8697395
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of t-PA, u-PA, PAI-1 and PAI-2 estimation in human bile by ELISA kits.
Kondera-Anasz Z; Michalski A; Gil D; Gil B; Starzewski J; Gonciarz Z
Med Sci Monit; 2000; 6(3):616-7. PubMed ID: 11208381
[TBL] [Abstract][Full Text] [Related]
17. Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis.
Sier CF; Verspaget HW; Griffioen G; Verheijen JH; Quax PH; Dooijewaard G; De Bruin PA; Lamers CB
Gastroenterology; 1991 Dec; 101(6):1522-8. PubMed ID: 1955118
[TBL] [Abstract][Full Text] [Related]
18. Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice.
Declerck PJ; Verstreken M; Collen D
Thromb Haemost; 1995 Nov; 74(5):1305-9. PubMed ID: 8607114
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase-type plasminogen activator system components in clear cell renal cell carcinoma patients without distant metastasis.
Fuessel S; Erdmann K; Taubert H; Lohse-Fischer A; Zastrow S; Meinhardt M; Bluemke K; Hofbauer L; Fornara P; Wullich B; Baretton G; Magdolen V; Wirth MP; Kotzsch M
BMC Cancer; 2014 Dec; 14():974. PubMed ID: 25519168
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
